ZERO WORLD RESEARCHアミノ酸・有機酸の学術文献データベース

Free glutaraldehyde gelatin microsphere loaded mesenchymal stem cells alleviate osteoarthritis by promoting <i>Ext1</i> expression.

遊離グルタルアルデヒドゼラチンマイクロスフェアに担持した間葉系幹細胞がExt1発現を促進し変形性関節症を軽減する (機械翻訳の邦題)

Theranostics2025Yuan Y, Xu L, Zhao Y, et al.
研究デザインその他の原著論文
対象ヒト・動物 併記

記録の確認項目

研究デザイン
その他の原著論文
対象
ヒト・動物 併記
出版年
2025
出典
doi.org
抄録の表示
表示あり
出版状態
有効な記録
状態確認日
2026/08/17
収集日
2026/08/04
鮮度
確認期限内
確認段階
自動処理
記録状態
公開

日本語要約(機械生成)

変形性関節症(OA)は慢性関節疾患であり、既存治療の効果は限定的である。本研究では、グルタルアルデヒドを含まないワンポット合成ゼラチンマイクロスフェアを新規生体材料として用い、間葉系幹細胞(MSCs)と共培養することで、OAで発現低下するExt1遺伝子の回復と免疫調節を検討した。OA患者の膝関節軟骨のトランスクリプトーム解析によりExt1の低下と免疫調節遺伝子の異常発現を確認した。ゼラチンマイクロスフェアはMSCsとの適合性が高く、細胞接着を促進し、Ext1遺伝子の過剰発現を誘導した。さらに免疫応答を調節し、OA症状を軽減した。本研究は、MSCsとゼラチンマイクロスフェアを用いた新規治療戦略を示し、Ext1発現促進と免疫調節によるOA症状の緩和効果を明らかにした。

この要約は公開抄録のみを根拠にAIが機械的に生成したものです。正確な内容は原文を確認してください。

抄録

Rationale: Osteoarthritis (OA) is a chronic joint disorder with limited treatment efficacy, necessitating innovative therapeutic strategies. This study explores one-pot-synthesized gelatin microspheres devoid of glutaraldehyde as a novel biomaterial for OA management. Focusing on the Ext1 gene, critical for cartilage development and downregulated in OA, we investigated its restoration and immune regulation using gelatin microspheres cultured with mesenchymal stem cells (MSCs). Methods: OA patients undergoing knee replacement surgery have their lateral compartment (remote zone) and medial compartment (lesion zone) cartilage collected for transcriptomic testing. The differential gene Ext1 is identified, and the expression of immune regulatory genes is examined. MSCs were cultured with gelatin microspheres to evaluate their compatibility and ability to promote cell attachment. The effects of the gelatin microspheres on Ext1 gene overexpression, immune regulation, and OA symptom mitigation were investigated through in vitro and in vivo experiments. Results: OA patients exhibit decreased expression of the Ext1 gene in the medial compartment (lesion zone) cartilage area, accompanied by abnormal expression of immune regulatory genes. The study demonstrated that the gelatin microspheres exhibited excellent compatibility with MSCs and facilitated their attachment. Culturing MSCs with the microspheres led to enhanced overexpression of the Ext1 gene, which is crucial for cartilage growth and development. Additionally, the microspheres regulated immune responses, contributing to a reduction in OA symptoms. Conclusion: This study introduces an innovative therapeutic strategy for osteoarthritis using gelatin microspheres cultured with MSCs. By promoting Ext1 gene overexpression and regulating immune responses, these microspheres effectively mitigate OA symptoms. The findings highlight the potential of this biomaterial as a promising treatment option for OA.

MeSH

AgedAnimalsCartilage, ArticularCells, CulturedExostosin 1FemaleGelatinGlutaralHumansMaleMesenchymal Stem Cell TransplantationMesenchymal Stem CellsMiceMicrospheresMiddle AgedN-AcetylglucosaminyltransferasesOsteoarthritis

DOI 10.7150/thno.109468

PMID 40213660

原文・出典を見る →